AU2003209828B2 - Novel chalcone derivatives and uses thereof - Google Patents

Description

WO 03/076407 PCT/AU03/00308 1 NOVEL CHALCONE DERIVATIVES AND USES THEREOF FIELD OF THE INVENTION The present invention relates to compounds useful in the modulation of potassium 5 channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation. 10 BACKGROUND Many autoimmune and chronic inflammatory diseases are related to immunoregulatory abnormalities. Diseases such as systemic lupus erythematosis, chronic rheumatoid arthritis, multiple sclerosis and psoriasis have in common the 15 appearance of autoantibodies and self-reactive lymphocytes. Multiple sclerosis is the most common neurological disease of young people. It is believed to cost more in medical care and lost income than any other neurological disease of young adults. 20 Multiple sclerosis affects the myelin sheaths of nerves. Myelin is an insulating material that coats most axons and allows rapid signal conduction over long distances by saltatory conduction. It is thought that antibodies and specialised cells of the immune system attack the myelin coating. This process leads to 25 inflammation and scarring (sclerosis) which damages blood vessels in the area by the formation of a lesion known as a plaque. These plaques are characterised by being infiltrated by cells of the immune system. This results in demyelination with the consequential loss of the rapid signal conduction. 30 Rheumatoid arthritis involves an inflammation in the lining of the joints and/or other internal organs. It is a systemic disease that affects the entire body, and as such it will typically affect many different joints. It is one of the most common forms of WO 03/076407 PCT/AU03/00308 2 arthritis, and is characterized by the inflammation of the membrane lining the joint, which causes pain, stiffness, warmth, redness and swelling. The inflamed joint lining, known as the synovium, can invade and damage bone and cartilage. The inflammation can cause the release of enzymes that may attack bone and 5 cartilage. The involved joint can lose its shape and alignment, resulting in pain and loss of movement. A possible method of treating these autoimmune and inflammatory diseases is by suppressing T cell proliferation and modulating their activation. 10 The early stages of T-cell activation may be conceptually separated into pre-Ca 2 + and post-Ca2+ events (Cahalan and Chandy 1997, Curr. Opin. Biotechnol. 8: 749). Following engagement of antigen with the T-cell antigen-receptor, activation of tyrosine kinases and the generation of inositol 1,4,5-triphosphate lead to the influx 15 of Ca2+ and the rise of cytoplasmic Ca2+ concentration. The rise in Ca2+ activates the phosphatase calcineurin, which then dephosphorylates a cytoplasmically localized transcription factor (N-FAT) enabling it to accumulate in the nucleus and bind to a promoter element of the interleukin-2 gene. Along with parallel events involving the activation of protein kinase C and ras, gene transcription leads to 20 lymphokine secretion and to lymphocyte proliferation. Some genes require long lasting Ca2+ signals while others require only a transient rise of Ca 2 +. Furthermore, Ca2+ immobilisation of the T-cell at the site of antigen presentation helps to cement the interaction between T-cell and the antigen-presenting cell and thereby facilitate local signalling between the cells. 25 Ion channels underlie the Ca2+ signal of T-lymphocytes. Ca2+ ions move across the plasma membrane through a channel termed the store-operated Ca2+ channel or the calcium release-activated Ca2+ channel. Two distinct types of potassium channels indirectly determine the driving force of calcium entry. The first is the 30 voltage-gated Kv1.3 channel (Cahalan 1985, J. Physiol. 385: 197; Grissmer 1990, Proc. Natl. Acad. Sci. USA 87: 9411; Verheugen 1995, J. Gen. Physiol. 105: 765; Aiyar 1996, J. Biol. Chem. 271: 31013; Cahalan and Chandy 1997, Curr. Opin.

WO 03/076407 PCT/AU03/00308 3 Biotechnol. 8: 749) and the second is the intermediate-conductance calcium activated potassium channel, lKCal (Grissmer 1993, J. Gen. Physiol. 102: 601; Fanger 1999 J. Biol. Chem. 274: 5746; Rauer 1999, J. Biol. Chem. 274: 21885; VanDorpe 1998, J. Biol. Chem. 273: 21542; Joiner 1997, Proc. Natl. Acad. Sci. 5 USA 94: 11013; Khanna 1999, J. Biol. Chem. 274: 14838; Lodgson 1997, J. Biol. Chem. 272: 32723; Ghanshani 1998, Genomics 51: 160). When these potassium channels open, the resulting efflux of K* hyperpolarizes the membrane, which in turn accentuates the entry of Ca 2 +, which is absolutely required for downstream activation events (Cahalan and Chandy 1997, Curr. Opin. Biotechnol. 8: 749). 10 The predominant voltage-gated channel in human T-lymphocytes is encoded by Kv1.3, a Shaker-related gene. Kv1.3 has been characterised extensively at the molecular and physiological level and plays a vital role in controlling T-lymphocyte proliferation, mainly by maintaining the resting membrane potential of resting T 15 lymphocytes. Inhibition of this channel depolarises the cell membrane sufficiently to decrease the influx of Ca2+ and thereby prevents downstream activation events. The Kv1.3 channel is a homotetramer, consisting of 4 identical Kv1.3 subunits which are assembled to form the functional channel. Advantageously, the homotetrameric Kv1.3 channel is almost exclusively located in T-lymphocytes. 20 Compounds which are selective Kv1.3 blockers are thus potential therapeutic agents as immunosuppressants for the prevention of graft rejection, and the treatment of autoimmune and inflammatory disorders. They could be used alone or in conjunction with other immunosuppressants, such as selective IKCal 25 blockers or cyclosporin, in order to achieve synergism and/or to reduce toxicity, especially of cyclosporin. At present there exist a number of non-selective K channels that will inhibit lymphocyte proliferation, but have adverse side effects. Other K channels exist in 30 a wide range of tissues including the heart and brain, and generally blocking these channels is undesirable.

P:\OPER\Jgc\l 2195130amendedpages. II l.doc4/03/2002 4 US Patent No. 5,494,895 discloses the use of a thirty-nine amino acid peptide, scorpion peptide margatoxin, as a selective inhibitor and probe of Kv1.3 channels present in human lymphocytes, and also as an immunosuppressant. However the use of this compound is limited by its potent toxicity. 5 International Patent Application publication Nos. WO 97/16438 and WO 97/16437, and US Patent No. 6,051,590 describe the use of the triterpene, correolide and related compounds as immunosuppressants in the treatment of conditions in mammals affected or facilitated by Kv1.3 inhibition. 10 US Patent 6,077,680 describes DNA segments and proteins of derived from sea anemone species, more particularly ShK toxin from Stichodactyla helianthus. The ShK toxin was found to block Kv1.1, Kv1.3, Kv1.4 and Kv1.6, but a mutant ShK K22DAP found to selectively block Kv1.3. Unfortunately the mutant was not 15 sufficiently stable for clinic use. ShK toxin has recently been shown to both prevent and treat experimental autoimmune encephalomyelitis in Lewis rats, an animal model for human multiple sclerosis (Beeton 2001,et al., Proc. Natl. Acad. Sci. USA 98:13942), by selectively 20 targeting T-cells chronically activated by the myelin antigen, MBP (myelin basic protein). The same study also indicated that chronically activated encephalitogenic rat T cells express a unique channel phenotype characterised by high expression of Kv1.3 channels (approximately 1500 per cell) and low numbers of IKCa1 channels (approximately 120 per cell). This channel phenotype is 25 distinct from that seen in quiescent and acutely activated cells and may be a functionally relevant marker for chronically activated rat T-lymphocytes. Recently khellinone, a substituted benzofuran and natural product from certain plants, and 8-Methoxypsoralen (8-MOP), both commercially available products, 30 were found to have blocking activity on the Kv1.3 channel.

WO 03/076407 PCT/AU03/00308 5 OMe O Me OH oMe CH 3 Khellinone 8-Methoxypsoralen WO 01/726680 (Cancer Research Ventures Limited) describes a number of 5 substituted chalcones, of the general formula 1-(4-methoxyphenyl)-3-(3,5 dimethoxyphenyl)prop-1-en-3-ones OMe O MeO O H a OMe OMe 10 for use in the treatment of antiproliferative conditions such as cancer, and anti inflammatory conditions such as rheumatoid arthritis. Chalcone is 1, 3-diphenyl-2 propen-1-one. SUMMARY OF THE INVENTION 15 The invention relates to compounds of the general formula I WO 03/076407 PCT/AU03/00308 6 Ri R 4 R R Rio Ri R R C C - C B A R6/C R7

OR

3 R2 Where: ring A is an optionally substituted fused carbocyclic or heterocyclic ring; 5 B is an optionally substituted aromatic or heteroaromatic ring;

R

1 and R 2 are independently selected from hydrogen, cyano, halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, 10 optionally substituted cycloalkyl, -OR, -C(O)R, -C(O)OR, -OC(O)R (where R is hydrogen or selected from an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl and aryl group), -C(O)NR'R", -NR'C(O)R" and -NR'R" (where R' and R" are independently selected from hydrogen or lower alkyl); 15 R 3 is hydrogen or optionally substituted alkyl, alkenyl or alkynyl group;

R

4 and R 5 are independently selected from hydrogen, hydroxy, alkyl, alkenyl; alkynyl and alkoxy; 20 or R 4 and R 5 together are =0, =S, =NR or =NOR, (where R is hydrogen or lower alkyl);

R

6 and R7 are independently selected from hydrogen, cyano, halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl 25 optionally substituted cycloalkyl, -OR, -C(O)R, -C(O)OR, -OC(O)R (where R is from hydrogen or is selected from an optionally substituted alkyl, alkenyl, alkynyl, WO 03/076407 PCT/AU03/00308 7 cycloalkyl and aryl group), -C(O)NR'R" and -NR'R" (where R' and R" are independently selected from hydrogen and lower alkyl); or R 3 together with R 7 together with the atoms to which they are attached form an 5 optionally substituted five or six membered heterocyclic ring;

R

8 and R 9 are independently selected from hydrogen, cyano, halo, nitro, a 5- or 6 membered nitrogen containing heterocyclic ring, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted 10 cycloalkyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, OR, -C(O)R, -C(O)OR, -OC(O)R (where R is hydrogen or is selected from an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl and aryl group), C(O)NR'R", -NR'C(O)R" and -NR'R" (where R' and R" are independently selected from hydrogen and lower alkyl); 15 or R 8 and R 9 are together =0, =S, =NR or =NOR, (where R is hydrogen or lower alkyl); or R 6 and R 8 together form a bond; 20 or R 4 , R', R 6 , R' and R 9 together with the atoms to which they are attached form an aromatic or heteroaromatic ring; or R , R7 and R 8 and the atoms to which they are attached, together with a ring 25 atom of B form a six membered aromatic or heteroaromatic ring fused to ring B; m = 0,1 or 2; each R 10 is independently selected from hydrogen, cyano, halo, nitro, optionally 30 substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and optionally substituted cycloalkyl; WO 03/076407 PCT/AU03/00308 8 with the proviso that R 3 is not -CH 2

CO

2 H when R 1 and R 2 are methoxy, m is 0, R 4 and R 5 together are =0, R 6 and R 8 together form a bond, R 7 and R 9 are hydrogen, ring A is an unsubstituted furyl ring and B is an optional substituted phenyl ring; 5 and with the proviso that when R 1 and R 2 are methoxy, R 3 is hydrogen, m is 0, R 4 and R 5 together are =0, B is an optional substituted phenyl ring and one of R 8 or

R

9 is hydrogen the other of R 8 or R 9 is not -CH 2 CN or optionally substituted forms thereof; 10 and with the proviso that ring A is not an unsubstituted cyclopentadiene ring, when

R

1 and R 2 are methoxy, R 3 is hydrogen, R 4 and R 5 together are =0, R 6 and R 8 together form a bond, R 7 and R 9 are hydrogen and B is an optionally substituted phenyl or pyridine ring; 15 and with the proviso that that R 3 is not -(CH 2

)

2 NR'R" (where R' and R" are independently hydrogen or alkyl, or together with the nitrogen to which they are attached form an unsubstituted piperidine ring), when R 1 and R 2 are methoxy, R 4 is hydroxy, R 5 , R 6 , R 7 , R 8 and R 9 are hydrogen, ring A is a five membered heterocyclic ring containing oxygen, and B is an optionally substituted phenyl ring; 20 and its salts and pharmaceutically acceptable derivatives thereof. In an aspect of the invention there is provided a method for the treatment or prevention of autoimmune or chronic inflammatory diseases, or the prevention of 25 rejection of foreign organ transplants and/or related afflictions, by the administration of a compound of formula I or a pharmaceutically acceptable derivative thereof, or a composition containing a compound of formula I or pharmaceutically acceptable derivatives thereof. 30 In another aspect of the invention there is provided a method of intentionally modulating potassium ion channel activity of T-cells by the application of a WO 03/076407 PCT/AU03/00308 9 compound of Formula I, or a pharmaceutically acceptable derivative thereof, to said T-cells. In a further aspect of the invention there is provided a pharmaceutical composition 5 for use as an immunosuppressant, the composition comprising an effective amount of compound of Formula I or pharmaceutically acceptable derivative thereof and optionally a carrier or diluent. 10 In another aspect of the invention there is provided a process for the production of compounds of formula I, its salts and pharmaceutically acceptable derivatives thereof. BRIEF DESCRIPTION OF THE DRAWINGS 15 Figure 1 depicts the effects [ 3 H]-Thymidine incorporation by human lymphocytes. DETAILED DESCRIPTION OF THE INVENTION The invention is based on the discovery that compounds of the general formula 1, 20 as described in the above Summary of the Invention can have useful properties as inhibitors of potassium cell channels, and particularly the Kv1.3 channel. Such compounds have significant potential as immunosuppressants for the treatment of autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. They may also be useful in the treatment or prevention of graft rejection. 25 The term alkyll" as used alone or in combination herein refers to a straight or branched chain saturated hydrocarbon group containing from one to ten carbon atoms, preferably one to six carbon atoms. The terms "C1.6 alkyl" and "lower alkyl" refer to such groups containing from one to six carbon atoms, preferably one to 30 four carbon atoms. Preferred alkyl groups include methyl ("Me"), ethyl ("Et"), n propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and the like.

WO 03/076407 PCT/AU03/00308 10 The term "alkenyl" means a two to ten carbon, preferably two to six carbon, straight or branched hydrocarbon containing one or more double bonds, preferably one or two double bonds. Preferred alkenyl groups include ethenylene, propenylene, 1, 3-butadienyl and 1, 3, 5-hexatrienyl. 5 The term "alkynyl" means a two to ten carbon, preferably two to six carbon, straight or branched hydrocarbon containing one or more triple bonds, preferably one or two triple bonds. 10 The term "alkoxy" as used alone or in combination herein refers to a straight or branched chain alkyl group covalently bound via an 0 linkage and the terms "C 1

.

6 alkoxy" and "lower alkoxy" refer to such groups containing from one to six carbon atoms. Preferred alkoxy and lower alkyl groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy and t-butoxy groups. 15 The term "aromatic" or "aryl" when used alone or in combination refers to an unsubstituted or optionally substituted monocyclic or bicyclic aromatic hydrocarbon ring system. The preferred aromatic ring are optionally substituted phenyl ("Ph") or naphthalenyl groups. 20 The more preferred aromatic or aryl group is the phenyl group which may be optionally substituted with up to five but more usually with one or two optional substituents. The preferred optional substituents include C 1

.

6 alkyl, C1.6 alkoxy, as well as cyano, trifluoromethyl and halo. 25 The term "benzofused" as used herein refers to a fused polycyclic ring system formed by joining an optionally substituted benzene ring to another ring, in such a way that the two rings share two ring atoms. 30 The term "carbocyclic" as used herein refers to a stable monocyclic or polycyclic ring system, wherein the ring atoms are only carbon atoms. The rings may be aromatic or non-aromatic. Examples of rings include cyclopentane, cyclohexane WO 03/076407 PCT/AU03/00308 11 and benzene. The carbocyclic ring may be optionally substituted with one or more substituents. The term "heterocyclic" as used herein refers to a stable monocyclic or polycyclic 5 ring system containing at least one ring of carbon atoms and other atoms selected from nitrogen, sulfur and oxygen. It includes aromatic (including what is sometimes referred to as pseudoaromatic) and non aromatic rings. The term "pseudoaromatic" refers to a ring system which is not strictly aromatic, but which is stabilised by means of delocalisation of electrons and behaves in a similar manner 10 to aromatic rings. The rings or ring systems generally include I to 9 carbon atoms in addition to the heteroatom(s) and may be saturated, unsaturated, aromatic or pseudoaromatic. 15 Examples of 5-membered monocyclic heterocycles include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl and examples of 6-membered monocyclic heterocycles include pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl, each of which may be optionally substituted. 20 The heterocyclic ring may be fused to a carbocyclic ring such as phenyl. Examples of 9 and 10-membered bicyclic heterocycles include indolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, 25 benzisothiazoyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl, benzotriazinyl and the like. Examples of preferred heterocyclic radicals include (optionally substituted) isoxazolyls, isothiazolyls, 1,3,4-oxadiazolyls, 1,3,4-thiadiazolyls, 1,2,4 30 oxadiazolyls, 1,2,4-thiadiazolyls, oxazolyls, thiazolyls, pyridinyls, pyridazinyls, pyrimidinyls, pyrazinyls, 1,2,4-triazinyls, 1,3,5-triazinyls, benzoxazolyls, benzothiazolyls, benzisoxazolyls, benzisothiazolyls, quinolinyls and quinoxalinyls.

WO 03/076407 PCT/AU03/00308 12 Examples of unsaturated 5-membered heterocyclic rings include oxazolyl, thiazolyl, imidazolyl, 1,2,3-triazolyl, isoxazolyl, isothiazolyl, pyrazolyl, furyl, thiophenyl and pyrrolyl. Examples of unsaturated 6-membered heterocyclic rings 5 include pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and 1,2,4-triazinyl. In a preferred embodiment, the heterocyclic ring is an aromatic ring selected from the group consisting of furyl, thienyl, pyridyl, purrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazoly, 1,2,4-oxadiazoly, 1,2,4 10 oxadiazol-5-one, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo~b]furanyl, benzo[b]thiophenyl, 1 H-indazolyl, benzimidazolyl and tetrazolyl. In another preferred embodiment, the heterocyclic ring is a non-aromatic ring 15 selected from the group consisting of pyrrolidinyl, imidazolinyl, 2-imidazolidonyl, 2 pyrrolidonyl, pyrrolin-2-onyl, tetrahydrofuryl, 1,3-dioxolanyl, piperidinyl, tetrahydropyryl, oxazolinyl, 1,3-dioxanyl, 1,4-piperazinyl, morpholinyl and thiomorpholinyl. 20 The term "heteroaromatic" as used herein is limited to aromatic (including pseudoaromatic) heterocycles as described above. Preferred rings include 5 or 6-membered monocyclic rings or an 8-11 membered bicyclic rings containing one, two, or three ring heteroatoms selected from nitrogen, oxygen and sulfur. 25 Examples of preferred heteroaromatic groups include isoxazolyl, oxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, furyl, pyrazolyl, pyridazinyl, furazanyl and thienyl. The ring may be attached to the parent structure through a carbon atom or through any heteroatom of the heteroaryl that results in a stable structure. Where indicated the heteroaryl may be fused to the parent structure. 30 The terms "halo" and "halogen" as used herein represent fluorine, chlorine, bromine or iodine substituent moieties, preferably bromine, chlorine or fluorine.

WO 03/076407 PCT/AU03/00308 13 In this specification unless otherwise defined "optionally substituted" means that a group may or may not be further substituted with one or more groups independently selected from: 5 * cyano, halo, -B(OH) 2 , nitro, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heterocyclyl; " -OR, -C(O)R, -C(O)OR, -OC(O)R, -SR, -SO 2 R, -SO 3 R, -OSO 3 R, 10 -S(O) 2 NHC(O)R, -S(O) 2

NHS(O)

2 R, -P0 3 , -OP0 3

R

2 and -C(O)NHS(0) 2 R (where R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl or heterocyclylalkyl); * -C(O)NR'R", -C(S)NR'R", -C(NR)NR'R", -C(=NCN)-NR'R", -C(=NR)NR'R", 15 -C(=NR')SR", -C(S)NR'R", -NR'C(O)R", -NR'C(O)OR", -NRC(0)NR'R", -NRC(S)NR'R", -NR'C(O)R", -NR'C(=NCN)SR", -NR'SO 2 R" and -NR'C(S)R" (where R, R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl and heterocyclyl); or 20 * -NR'R" (where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl and alkoxy, or R' and R" together with the N atom to which they are attached form a six membered ring); Where the optional substituent includes an alkyl, alkenyl, alkynyl or cycloalkyl 25 moiety, that moiety may itself be substituted with one or more of groups independently selected from halo, hydroxy, cyano, -B(OH) 2 , -OSO 3 H, -OP0 3

H

2 , tetrazolyl, loweralkoxy, -S(O) 2 NHC(O)R, -C(O)NHS(O) 2 R, -COR, -COOR (where R is hydrogen, lower alkyl or phenyl) and -NR'R", (where R', and R" are independently hydrogen or lower alkyl or R' and R" together with the N atom to 30 which they are attached form a six membered ring).

WO 03/076407 PCT/AU03/00308 14 Where the optional substituent includes a carbocyclic or heterocyclic ring, that ring may be substituted at one or more substitutable ring positions with one or more groups independently selected from alkyl (preferably lower alkyl), alkoxy (preferably lower alkoxy), nitro, monoalkylamino (preferably a lower alkylamino), 5 dialkylamino (preferably a di[lower]alkylamino, cyano, halo, haloalkyl (preferably trifluoromethyl), alkanoyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl amido (preferably lower alkyl amido), alkoxyalkyl (preferably a lower alkoxy[lower]alkyl), alkoxycarbonyl (preferably a lower alkoxycarbonyl), alkylcarbonyloxy (preferably a lower alkylcarbonyloxy) and aryl 10 (preferably phenyl), said aryl being optionally substituted by halo, lower alkyl and lower alkoxy groups. The salts of the compound of formula I are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts 15 also fall within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts. The term "pharmaceutically acceptable derivatives" includes pharmaceutically acceptable esters, prodrugs, solvates and hydrates, and pharmaceutically 20 acceptable addition salts of the compounds or the derivatives. Pharmaceutically acceptable derivatives may include any pharmaceutically acceptable salt, hydrate or any other compound or prodrug which, upon administration to a subject, is capable of providing (directly or indirectly) a compound of formula I or an antivirally active metabolite or residue thereof. 25 The pharmaceutically acceptable salts include acid addition salts, base addition salts, salts of pharmaceutically acceptable esters and the salts of quaternary amines and pyridiniums. The acid addition salts are formed from a compound of the invention and a pharmaceutically acceptable inorganic or organic acid 30 including but not limited to hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, toluenesulphonic, benzenesulphonic, acetic, propionic, ascorbic, citric, malonic, fumaric, maleic, lactic, salicyclic, sulfamic, or tartartic acids. The WO 03/076407 PCT/AU03/00308 15 counter ion of quarternary amines and pyridiniums include chloride, bromide, iodide, sulfate, phosphate, methansulfonate, citrate, acetate, malonate, fumarate, sulfamate, and tartate. The base addition salts include but are not limited to salts such as sodium, potassium, calcium, lithium, magnesium, ammonium and 5 alkylammonium. Also, basic nitrogen-containing groups may be quaternised with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others. The salts may be made in a known manner, for example by treating the compound with an appropriate acid or base in the presence of a suitable 10 solvent. The compounds of the invention may be in crystalline form or as solvates (e.g. hydrates) and it is intended that both forms be within the scope of the present invention. The term "solvate" is a complex of variable stoichiometry formed by a 15 solute (in this invention, a compound of the invention) and a solvent. Such solvents should not interfere with the biological activity of the solute. Solvents may be, by way of example, water, ethanol or acetic acid. Methods of solvation are generally known within the art. 20 The term "pro-drug" is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, for example, compounds where a free hydroxy group is converted into an ester derivative or a ring nitrogen atom is converted to an N-oxide. Examples of ester derivatives 25 include alkyl esters, phosphate esters and those formed from amino acids, preferably valine. Any compound that is a prodrug of a compound of the invention is within the scope and spirit of the invention. The term "pharmaceutically acceptable ester" includes biologically acceptable 30 esters of compound of the invention such as sulphonic, phosphonic and carboxylic acid derivatives.

WO 03/076407 PCT/AU03/00308 16 It will be appreciated that compound of formula I and some derivatives thereof may have at least one asymmetric centre, and therefore are capable of existing in more than one stereoisomeric form. The invention extends to each of these forms individually and to mixtures thereof, including racemates. The isomers may be 5 separated conventionally by chromatographic methods or using a resolving agent. Alternatively the individual isomers may be prepared by asymmetric synthesis using chiral intermediates. Where the compound has at least one carbon-carbon double bond, it may occur in Z- and E- forms and all isomeric forms of the compounds being included in the present invention. 10 The invention provides a method of preventing or treating autoimmune or chronic inflammatory diseases, or the prevention of rejection of foreign organ transplants and/or related afflictions, by the administration of a compound of formula I, or a pharmaceutically acceptable derivative thereof, or a composition containing a 15 compound of the general formula I or a pharmaceutically acceptable derivative thereof. With reference to the general formula 1, it is preferred that the fused ring A is an optionally substituted ring selected from the following (the two dashed lines on the 20 right hand side of the rings indicate the position at which the ring A is fused to the phenyl ring): N NNN - 0 b" X 0 25 where X is 0, S or NR, where R is hydrogen, lower alkyl or oxygen; or WO 03/076407 PCT/AU03/00308 17 X -1 Y Y X where X is N, and Y is 0, S or NR and R is hydrogen, lower alkyl or oxygen. More preferably ring A is an optionally substituted ring of the structure: R R N > N N> N 0 S N 0 SDI. "- N N R 0 S - S I0 5 R NN NN N where R is hydrogen or lower alkyl. Most preferably A is an optionally substituted ring of the structure: 10 'e, lor Preferably ring A is optionally substituted with halo, lower alkyl, benzyl or C(O)C 6

H

5

.

WO 03/076407 PCT/AU03/00308 18 Preferably R 1 and R 2 are independently selected from hydrogen; halogen; hydroxy; lower alkoxy, optionally substituted benzyl, optionally substituted phenyl, optionally substituted diphenyl, optionally substituted phenoxy and optionally substituted benzoxy group. More preferably R 1 and R 2 are independent selected from 5 hydrogen, lower alkoxy, optional substituted benzoxy and optionally substituted phenoxy. Most preferably they are both methoxy groups. Preferably R 3 is hydrogen or optionally substituted lower alkyl, or together with R 6 form a five or six membered heterocylic ring. If R 3 and R 6 form a heterocyclic ring 10 it is preferred that the ring is not heteroaromatic and that one or more of the ring carbons is substituted with =0, =S or =NR, where R is hydrogen or lower alkyl. Preferably R 3 is selected from hydrogen, unsubstituted alkyl (preferably lower alkyl), -(CH 2 )nNR'R" (where n is from I to 4 and R' and R" are independently 15 hydrogen or lower alkyl, or R' and R" together with the N atom to which they are attached form a six membered ring) and -(CH 2 )nR 20 , (where n is from I to 6 and

R

20 is selected from phenyl, -OSO 3 H, -OP0 3

H

2 , -CO 2 H, tetrazolyl, -B(OH) 2 , CO 2 R, -S(0) 2 NHC(O)R and -S(0) 2 NHS(0) 2 R, where R is lower alkyl). 20 Most preferably R 3 is hydrogen, methyl or benzyl optionally substituted with 1 to 3 halo or lower alkyl groups. Preferably R 4 and R 5 are independently hydrogen or hydroxy, or together are =0. Most preferably R 4 and R 5 together are =0. 25 Preferably R 6 is selected from hydrogen, halogen (preferably bromine), -CN, C(O)R (where R is lower alkyl or phenyl), -C(O)OR, (where R is hydrogen or lower alkyl), optionally substituted alkyl, (such as arylalkyl or -(CH 2 )nCO 2 R, where R is H or methyl and n is from 1 to 6) and optionally substituted alkenyl group (such as 30 phenylethylene); or preferably R 6 and R 8 together form a bond between the carbons to which they are attached WO 03/076407 PCT/AU03/00308 19 Preferably R 7 is hydrogen. Preferably R 8 and R 9 are independently selected from hydrogen; lower alkyl, an optionally substituted cyanoalkyl group (such as -CHR(CN) where R is selected 5 from hydrogen, OH, lower alkyl and lower alkoxy), -C(O)R (where R is optionally substituted lower alkyl, optionally substituted lower alkoxy or optionally substituted phenyl), -NR'R" (where R' and R" are independently selected from hydrogen and 0 NH lower alkyl), and N=~=N 10 More preferably R 8 together with R 6 form a carbon double bond, and R 9 is hydrogen. Preferably m is 0 or 1, most preferably 0. 15 Preferably B is an optionally substituted phenyl ring. This ring may also be benzofused or fused to a heterocyclic ring. Preferred forms of B include an optionally substituted phenyl or naphthalene ring, or a ring system of the structure C O 0 C 20 Alternatively B is an optionally substituted and optionally benzofused heteroaromatic ring. Preferred heteroaromatic rings include pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, pyridine, pyran and pyrimidine. When B is a benzofused heteroaromatic ring, it is preferrably an optionally substituted indole, quinoline or isoquinoline ring system. 25 WO 03/076407 PCT/AU03/00308 20 In addition to the above forms of B, R 6 , R7 and R 8 together with a ring carbon atom of Ring B can form a six membered aromatic ring fused to ring B to provide a compound of the following general formula: R R R R' A B R2 5 Preferably B is a phenyl ring optionally substituted with one or more substituents independently selected from * halo, cyano, -NO 2 , -SO 3 , -OSO 3 H, -OP0 3

H

2 , -P0 3 and -B(OH) 2 ; * -NR'R" (where R' and R" are independently hydrogen or lower alkyl); 10 * -NR'C(O)R" (where R' and R" are independently hydrogen or lower alkyl); e phenyl and tetrazolyl; * -OR, -C(O)R, and -C(O)OR (where R is hydrogen, optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted phenylloweralkyl (where the optional substituents are independently selected from lower alkyl, 15 halo and -NR'R" where R' and R" are independently hydrogen or lower alkyl); * -C(O)NHSO 2 R'" and -S(O) 2 NHC(O)R'" (where R"' is lower alkyl); optionally substituted lower alkyl such as -CH 3 , -CH(CH 3

)

2 , -CH 2

B(OH)

2 ,

-CH

2

PO

3 , -CH 2

SO

3 , -CH 2

OPO

3

H

2 , -CH 2

OSO

3 H, -CH 2

C(O)NHSO

2 R"',

-CH

2

S(O)

2 NHC(O)R"' (where R"' is lower alkyl), -CH 2

C

6

H

5 , -CH 2 -tetrazolyl, 20 -(CH 2 )nNR'R" (where n is from 1 to 4 and R' and R" are independently hydrogen or lower alkyl); -CF 3 , -CF 2

B(OH)

2 , -CF 2

PO

3 , -CF 2

SO

3 , -CF 2

OPO

3

H

2 ,

-CF

2

OSO

3 H, -CF 2

C(O)NHSO

2 R"', -CF 2

S(O)

2 NHC(O)R'" (where R"' is lower alkyl) -CF 2

C

6

H

5 and -CF 2 -tetrazolyl. 25 In a preferred form of the invention, B is meta substituted (in respect to the bond that joins B to the rest of the general formula) with an acidic group. Non limiting WO 03/076407 PCT/AU03/00308 21 examples of acidic groups include -(CH 2 )nR 20 , where n is from 0 to 6, and R 20 is selected from -OSO 3 H, -OP0 3

H

2 , -CO 2 H, tetrazolyl, -B(OH) 2 , -S(O) 2 NHC(O)R', C(O)NHS(O) 2 R' (where R' is lower alkyl), -OH, -C 6

H

4 OH, -CF 2

PO

3 and -SO 3 , most preferably B is substituted with one or more hydroxy groups. B may also have one 5 or more additional substituents. A preferred form of the invention pertains to the use of compounds of formula 11 for preventing or treating autoimmune or chronic inflammatory diseases, or the prevention of rejection of foreign organ transplants and/or related afflictions. 10 OR12 0 R8 R 11 CCH LCH==-CH-B O , R6 R I OR 1 where B is as earlier described, m is 0 or 1, and R 6 and R 8 are hydrogen or together form a double bond, and R" is hydrogen, lower alkyl, halogen and 15 -C(O)C 6

H

5 , R 12 and R 13 are independently selected from hydrogen, alkyl, optionally substituted phenyl, optionally substituted benzyl, -(CH 2 )nNR'R" (where n is from 1 to 4 and R' and R" are independently hydrogen or lower alkyl) and -(CH 2 )nR 20 , where n is from I to 4, and R 20 is selected from -OSO 3 H, -OP0 3

H

2 , -CO 2 H, tetrazolyl, -B(OH) 2 , -S(0) 2 NHC(O)R and -C(O)NHS(O) 2 R (where R is lower alkyl) 20 and R 14 is hydroxy or alkoxy, preferably hydroxy or methoxy. A more preferred form of the invention is the use of compounds of the formula Ill for preventing or treating autoimmune or chronic inflammatory diseases, or the prevention of rejection of foreign organ transplants and/or related afflictions.

WO 03/076407 PCT/AU03/00308 22 OCH3 O R 8

R

CH CH-==CH B OR6 OH OCH3 III where B is as earlier described, m is 0 or 1, and R 6 and R 8 are hydrogen or together form a bond, and R' 1 is hydrogen, lower alkyl, halogen or -C(O)C 6

H

5 . 5 A more preferred form of the invention is the use of compounds of the formula IV for preventing or treating autoimmune or chronic inflammatory diseases, or the prevention of rejection of foreign organ transplants and/or related afflictions. RM / B 0 OH IV OCH3 10 where B is an optionally substituted ring or ring system selected from phenyl,naphthalenyl, pyridinyl, pyrrolyl, furyl, indolyl, quinolinyl, isoquinolinyl, 0 NH thiophenyl and N=N all of which may be optionally substituted with one or more substituents. 15 The optional substituents of B are preferably independently selected from OP0 3

H

2 , -PO 3 , -OS0 3 , -SO 3 , -CH 2

PO

3 , -CH 2

SO

3 , -CO 2 H, -CH 2

CO

2 H, -CF 2

PO

3 , CF 2

SO

3 , -OH, -B(OH) 2 , -OCH 3 , -OCH 2

CH

3 , -CF 3 , -CH 3 , -CH 2

CH

3 , -CH(CH 3

)

2 , - WO 03/076407 PCT/AU03/00308 23

C

6

H

5 , -OC 6

H

5

-OC

6

H

4

CH

3 , -tetrazolyl, -CH 2 tetrazolyl, -CF2tetrazolyl, -NHC(O)CH 3 , 0 -F, -Cl, -Br, -CN, -OCH 2

CH

2

N(CH

2

CH

3

)

2 , -NO 2 , -N(CH 3

)

2 and N- . Another preferred form of the invention is the use of compounds of the formula V 5 for preventing or treating autoimmune or chronic inflammatory diseases, or the prevention of rejection of foreign organ transplants and/or related afflictions. OR 12 R 5 0 16 18 0 OH R 16R1 OR 13 R 1 V 10 where R" is hydrogen, lower alkyl, halogen or -C(O)C 6

H

5 R , preferably hydrogen, and R 1 3 are independently selected from hydrogen, alkyl (preferably lower alkyl), optionally substituted phenyl and optionally substituted benzyl; R 13 also be selected from -(CH 2 )nNR'R" (where n is from 1 to 4 and R' and R" are independently selected from hydrogen and lower alkyl) and -(CH 2 )nR 20 (where n is 15 from 0 to 6 and R 20 is selected from -OSO 3 H, -OP0 3

H

2 , -CO 2 H, -tetrazolyl,

-B(OH)

2 , -S(O) 2 NHC(O)R and -C(O)NHS(0) 2 R where R is lower alkyl).

R

15 , R 16 , R 1 7 and R 1 8 are independently selected from hydrogen, -OP0 3

H

2 , -P0 3 , -OS0 3 , -SO 3 , -CH 2

PO

3 , -CH 2

SO

3 , -CO 2 H, -CH 2

CO

2 H, -CF 2

PO

3 , -CF 2

SO

3 , -OH, 20 -B(OH) 2 , -OCH 3 , -OCH 2

CH

3 , -CF 3 , -CH 3 , -CH 2

CH

3 , -CH(CH 3

)

2 , -C 6

H

5 , -OC 6

H

5 WO 03/076407 PCT/AU03/00308 24

-OC

6

H

4

CH

3 , -tetrazolyl, -CH 2 tetrazolyl, -CF 2 tetrazolyl, -NHC(O)CH 3 , -F, -Cl, -Br, 0 NH -CN, -OCH 2

CH

2

N(CH

2

CH

3

)

2 , -NO 2 , -N(CH 3 ) and N N

R

1 9 is selected from -(CH 2 )nR 20 , where n is from 0 to 6, and R 20 is selected from hydrogen (when n is other than 0), -OSO 3 H, -OPO 3

H

2 , -CO 2 H, -tetrazolyl, -B(OH) 2 , 5 ~S(O) 2 NHC(O)R', -C(O)NHS(O) 2 R', -OR (where R' is lower alkyl), -OR-C 6

H

4 0H,

-CF

2

PO

3 and -SO 3 . Preferably R 1 9 is hydroxy. Another preferred form of the invention is the use of compounds of the formula VI for preventing or treating autoimmune or chronic inflammatory diseases, or the 10 prevention of rejection of foreign organ transplants and/or related afflictions. OR O Ris5

R

11 OH O 14 1R1 VI where R 1 is hydrogen, lower alkyl, halogen or -C(O)C 6

H

5 , preferably hydrogen;

R

12 and R 13 are independently selected from hydrogen, alkyl (preferably lower 15 alkyl), optionally substituted phenyl and optionally substituted benzyl; and R 13 may also be selected from -(CH 2 )nNR'R" (where n is from 1 to 4 and R' and R" are independently hydrogen or lower alkyl) or -(CH 2 )nR 20 , where n is from 0 to 6, and R 20 is selected from -OSO 3 H, -OP0 3

H

2 , -CO 2 H, tetrazolyl, -B(OH) 2 ,

-S(O)

2 NHC(O)R and -C(O)NHS(O) 2 R where R is lower alkyl); 20 R 1 4 is hydroxy, alkoxy, -(CH 2 )nNR'R" (where n is from I to 4 and R' and R" are independently hydrogen or lower alkyl) and -(CH 2 )nR 20 , where R 20 is selected from

-OSO

3 H, -OP0 3

H

2 , -CO 2 H, tetrazolyl, -B(OH) 2 , -S(0) 2 NHC(O)R and

-S(O)

2

NHS(O)

2 R where R is lower alkyl. Preferably R 1 4 is hydroxy or methoxy.

WO 03/076407 PCT/AU03/00308 25

R

15 , R 1 6 , R 1 7 and R 18 are independently selected from hydrogen, -OPO 3

H

2 , -P0 3 , -OS0 3 , -SO 3 , -CH 2

PO

3 , -CH 2

SO

3 , -CO 2 H, -CH 2

CO

2 H, -CF 2

PO

3 , -CF 2

SO

3 , -OH,

-B(OH)

2 , -OCH 3 , -OCH 2

CH

3 , -CF 3 , -CH 3 , -CH 2

CH

3 , -CH(CH 3

)

2 , -C 6

H

5 , -OC 6

H

5

-OC

6

H

4

CH

3 , -tetrazolyl, -CH 2 tetrazolyl, -CF 2 tetrazolyl, -NHC(O)CH 3 , -F, -Cl, -Br, 0 NH 5 -CN, -OCH 2

CH

2

N(CH

2

CH

3

)

2 , -NO 2 , -N(CH 3 ) and N N The compounds of formula I to VI, pharmaceutically acceptable derivatives thereof, and compositions thereof, may be useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and / or related 10 afflictions, diseases and illnesses. The potassium channel activity inhibited by the compounds of Formula I to VI is may be a voltage-gated potassium channel, for example, Kv1.1-Kv1.7, or heteromultimers containing these proteins and/or accessory proteins such as beta 15 subunits. Compounds of the Formula I to VI may inhibit the potassium ion channel activity of the voltage-gated potassium channel, Kv1.3 channel of a T-cell. 20 The compounds of the invention may be useful in respect of a number of ailments. They may be useful in the therapeutic or prophylactic treatment of the resistance to transplantation of organs or tissue (such as heart, kidney, liver, lung, bone marrow, cornea, pancreas, intestinum tenue, limb, muscle, nervus, medulla ossium, duodenum, small-bowel, medulla ossium, skin, pancreatic islet-cell, etc. 25 including xeno transplantation), graft-versus-host diseases; rheumatoid arthritis, systemic lupus erythematosus, nephrotic syndrome lupus, Palmo-planter pustulosis, Hashimoto's thyroiditis, multiple sclerosis, Guillain-Barre syndrome, myasthenia gravis, type I diabetes uveitis, juvenile-onset or recent-onset diabetes mellitus, diabetic neuropathy, posterior uveitis, allergic encephalomyeitis, WO 03/076407 PCT/AU03/00308 26 glomerulonephritis, infectious diseases caused by pathogenic microorganisms, inflammatory and hyperproliferative skin diseases, psoriasis, atopical dermatitis, contact dermatitis, eczematous dermatitises, seborrhoeis dermatitis, Lichen planus, Pemphigus, bullous pemphigoid, Epidermolysis bullosa, urticaria, 5 angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Lupus erythematosus, acne, Alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, Scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada 10 syndrome, sarcoidosis, etc.; pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma, chronic or inveterate asthma, late asthma and airway hyper responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, 15 necrotizing enterocolitis, intestinal lesions associated with thermal burns and leukotriene B 4 -mediated diseases, Coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Good-pasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, 20 Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial 25 pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T-cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, 30 glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth; muscular dystrophy; Pyoderma and Sezary's syndrome, Sjoegren's WO 03/076407 PCT/AU03/00308 27 syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, for example, thrombosis and cardiac infraction, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, 5 toxinosis caused by lung-oxygen or drug, for example, paracort and bleomycins, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis, pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn; dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental 10 pollution, aging, carcinogenis, metastasis of carcinoma and hypobaropathy; disease caused by histamine or leukotriene-C 4 release; Berger's disease, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic 15 cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, preventing or treating activity of cytomegalovirus infection, HCMV infection, and antiinflammatory activity; and treatment of immunodepression or a disorder involving immunodepression, including AIDS, cancer, senile dementia, trauma, 20 chronic bacterial infection, type II diabetes mellitus as glucose-dependent insulin secretagogues, cardiac arrhythmias such as atrial or ventricular fibrillation, epilepsy, muscular fasciculations, urinary incontinence, certain central nervous system disorders via modulating neural conduction or neurotransmitter release. 25 For certain of the above mentioned conditions it is clear that the compounds may be used prophylactically as well as for the alleviation of acute symptoms. References herein to "treatment" or the like are to be understood to include such prophylactic treatment, as well as treatment of acute conditions. 30 In another aspect, the invention provides a method of modulating potassium ion channel activity of T cells by the application of a compound according to Formula I to VI to said T cells.

WO 03/076407 PCT/AU03/00308 28 The compounds of the invention, pharmaceutically acceptable derivatives thereof, and compositions containing the compounds or pharmaceutically acceptable derivatives thereof, may also be used in the treatment of autoimmune diseases, in 5 the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses. In such treatment it is preferred that the potassium channel activity inhibited by the compound of Formula I to VI is a voltage-gated potassium channel, for example, 10 Kv1.1-Kv1.7. More preferably the potassium ion channel activity is the voltage gated potassium channel, Kv1.3 of a T-cell. Preferably the compound selectively inhibits the Kv1.3 channel, and optionally also the Kv1. I and / or Kv1.2 channels. In a further aspect of the invention there is provided a pharmaceutical composition 15 for use as an immunosuppressant, the composition comprising an effective amount of compound of Formula 1, pharmaceutically acceptable derivative thereof, and optionally a carrier or diluent. The compositions of this aspect of the invention may further contain one or more 20 other immunosuppressive compounds. For example the compositions may contain a second immunosuppressive agent such as azathioprine, brequinar sodium, deoxyspergualin, mizaribine, mycophenolic acid morpholino ester, cyclosporin, FK-506 and rapamycin. 25 By "composition" is intended to include the formulation of an active ingredient (the active being at least one compound of the invention or a pharmaceutically acceptable derivative thereof) with encapsulating material as carrier, to give a capsule in which the active ingredient (with or without other carrier) is surrounded by carriers. 30 The pharmaceutical compositions or formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral WO 03/076407 PCT/AU03/00308 29 (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The compounds of the invention, together with a conventional adjuvant, carrier, or 5 diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including 10 subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any 15 suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Formulations containing ten (10) milligrams of active ingredient or, more broadly, 0.1 to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms. 20 The compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention. 25 For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispensable granules. A solid carrier can be one or more substances which 30 may also act as diluents, flavouring agents, solubilisers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

WO 03/076407 PCT/AU03/00308 30 In powders, the carrier is a finely divided solid that is in a mixture with the finely divided active component. 5 In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from five or ten to about seventy 10 percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier 15 providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration. 20 For preparing suppositories, a low melting wax, such as admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify. 25 Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Liquid form preparations include solutions, suspensions, and emulsions, for 30 example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

WO 03/076407 PCT/AU03/00308 31 Sterile liquid form compositions include sterile solutions, suspensions, emulsions, syrups and elixirs. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent 5 or a mixture of both. The compositions according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre 10 filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or 15 by lyophilisation from solution, for constitution with a suitable vehicle, eg. sterile, pyrogen-free water, before use. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and 20 thickening agents, as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other 25 well known suspending agents. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, 30 in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.

WO 03/076407 PCT/AU03/00308 32 For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or 5 oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. 10 Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. 15 Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined 20 volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump. To improve nasal delivery and retention the compounds according to the invention may be encapsulated with cyclodextrins, or formulated with other agents expected to enhance delivery and retention in the nasal mucosa. 25 Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, 30 carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

WO 03/076407 PCT/AU03/00308 33 Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and 5 polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler. 10 In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 to 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronisation. 15 When desired, formulations adapted to give sustained release of the active ingredient may be employed. The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate 20 quantities of the active component. The unit dosage form can be a packaged preparation, the package containing- discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. 25 The invention also includes the compounds in the absence of carrier where the compounds are in unit dosage form. The amount of compound of formula I administered may be in the range from 30 about 10 mg to 2000 mg per day, depending on the activity of the compound and the disease to be treated.

WO 03/076407 PCT/AU03/00308 34 Liquids or powders for intranasal administration, tablets or capsules for oral administration and liquids for intravenous administration are the preferred compositions. 5 In a further aspect of the invention there is provided new compounds of the general formula I to VI as described above. The compounds of the general formula V and VI are particularly preferred In further aspect of the invention there is provided a process for the production of 10 the compounds of the formula I to VI, and more preferably of the formula V and VI. Chalcones are conveniently synthesized by reaction of an acetophenone with an aryl aldehyde. A useful source of benzofuran-containing acetophenones is natural products such as khellinone. 15 For example, reaction of khellinone with benzaldehyde in aqueous sodium hydroxide solution furnishes the compound , as shown below: RPhC(=O)H, OMe 0 NaOH OMe O Me SoH OH OMe OMe Khellinone, Kd (KvL3) 70mM Khellin chalcone derivative, Kd (Kvl.3) 0.17mM 20 Variations of this reaction include first modifying khellinone to create a derivative thereof by adding, removing or modifying one or more of the functional groups attached to the ring system. For example, the methoxy groups could be selectively manipulated to provide to higher alkyl derivatives of khellinone and 25 used in the above scheme as precursors for compound formation.

WO 03/076407 PCT/AU03/00308 35 Another starting material is Khellin, which can be regarded as a protected khellinone. This compound could be demethylated and the resulting hydroquinone selectively alkylated. As can be seen below hydrogen bonding shown as dotted line will stabilise the hydrogen of one of the phenolic hydroxy groups. A weak 5 base together with an alkylating agent such as Mel or Etl will only alkylate the non hydrogen bonded phenolic hydroxy group. A strong base, such as Cs2CO3, is required together with an alkylating agent such as Mel or Etl to selectively alkylate the hydrogen-bonded phenolic OH.

WO 03/076407 PCT/AUO3/00308 36 0~ 0C Ml0' 0' Me M K2C0C * 01M I Me Et 0M30 ort0 Me Me M el Ot e Iw 0 EtO0 Me~ QEt WO 03/076407 PCT/AU03/00308 37 These modified khellinones could then be reacted to give chalcones in the usual way. Another variation is to add, remove or modify the substituents of the product to 5 form new derivatives. This could be achieved by using standard techniques for functional group inter-conversion, well known in the industry such as those described in Comprehensive organic transformations: a guide to functional group preparations by Larock R C, New York, VCH Publishers, Inc. 1989 10 Examples of functional group inter-conversions are: -C(O)NRR' from -CO 2

CH

3 by heating with or without catalytic metal cyanide, e.g. NaCN, and HNRR' in CH 3 0H; -OC(O)R from -OH with e.g., CIC(O)R' in pyridine; -NR-C(S)NR'R" from -NHR with an alkylisothiocyanate or thiocyanic acid; -NRC(O)OR from -NHR with alkyl chloroformate; -NRC(O)NR'R" from -NHR by treatment with an isocyanate, e.g. 15 HN=C=O or RN=C=O; -NRC(O)R' from -NHR by treatment with CIC(O)R' in pyridine; -C(=NR)NR'R" from -C(NR'R")SR'" with H 3 NR*OAc- by heating in alcohol; -C(NR'R")SR from -C(S)NR'R" with R-l in an inert solvent, e.g. acetone; -C(S)NR'R" (where R' or R" is not hydrogen) from -C(S)NH 2 with HNR'R"; -C(=NCN)-NR'R" from -C(=NR'R")-SR with NH 2 CN by heating in anhydrous 20 alcohol, alternatively from -C(=NH)-NR'R" by treatment with BrCN and NaOEt in EtOH; -NR-C(=NCN)SR from -NHR' by treatment with (RS) 2 C=NCN; -NR"SO 2 R from -NHR' by treatment with CISO 2 R by heating in pyridine; -NR'C(S)R from -NR'C(O)R by treatment with Lawesson's reagent [2,4-bis(4-methoxyphenyl) 1,3,2,4-dithiadiphosphetane-2,4-disulfide]; -NRSO 2

CF

3 from -NHR with triflic 25 anhydride and base, -CH(NH 2 )CHO from -. CH(NH 2 )C(O)OR' with Na(Hg) and HCI/EtOH; -CH 2 C(O)OH from -C(O)OH by treatment with SOC1 2 then CH 2

N

2 then

H

2 0/Ag 2 O; -C(O)OH from -CH 2

C(O)OCH

3 by treatment with PhMgX/HX then acetic anhydride then Cr0 3 ; R-OC(O)R' from RC(O)R' by R"CO 3 H; -CCH 2 OH from -C(O)OR' with Na / R'OH; -CHCH 2 from -CH 2

CH

2 OH by the Chugaev reaction; 30 -NH 2 from -C(O)OH by the Curtius reaction; -NH 2 from -C(O)NHOH with TsCI/base then H 2 0; -CHC(O)CHR from -CHCHOHCHR by using the Dess-Martin Periodinane regent or Cr0 3 / aqH 2

SO

4 / acetone; -C 6

H

5 CHO from -C 6

H

5

CH

3 with WO 03/076407 PCT/AU03/00308 38 CrO 2

CI

2 ; -CHO from -CN with SnCl 2 / HCI; -CN from -C(O)NHR with PCI 5 ; -CH 2 R from -C(O)R with N 2

H

4 / KOH. Functional group inter-conversion reactions may require other substituents to be 5 protected during the reaction. Suitable protecting groups are well known in industry and have been described in many references such as Protecting Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New York, 1981. In order that the present invention may be more readily understood we provide the 10 following examples. Example 1 Khellinone (1 mmol) and benzaldehyde (1.5 mmol) were stirred in 2M aq. NaOH 15 (1ml) overnight. The reaction mixture was diluted methanol ("MeOH") (3ml), acidified with 10% aq. citric acid and the precipitated product filtered and recrystallized from methanol to give the product as cinnamon needles (325 mg, 78%). 20 Example 2 The product of Example 1 (0.15 mmol) in dichloromethane ("DCM") (1ml) was treated with Et 3 SiH (2 eq.) and trifluoroacetic acid ("TFA") (Immol), and stirred for 3h under an atmosphere of dry nitrogen. The reaction mixture was diluted with 25 cyclohexane, and on concentrating, the product crystallised out as yellow needles, which were then filtered off (46mg, 93%). Example 3 30 A suspension of the product of example 1 (0.5 mmol) and 10%Pd/C (60mg) in ethylacetate ("EtOAc") (3ml) was subjected to hydrogenation by balloon overnight.

WO 03/076407 PCT/AU03/00308 39 The reaction mixture was filtered through celite, the filtrate concentrated, and the product recrystallized from MeOH as pale yellow needles (103 mg, 63%). Example 4 to 58 5 These were all made by a similar procedure to that described for Example 1, that is, by the reaction of khellinone with an aldehyde. Thus, khellinone (0.4 mmol) and the appropriate aldehyde (0.6 mmol) or an appropriate derivative thereof were stirred in 2M aq. NaOH (1ml) and MeOH (Iml) overnight. The reaction mixture 10 was neutralised with acetic acid and the precipitated product filtered and recrystallised from DCM/MeOH. Noteworthy variations include: 15 Examples 13, 20 and 40 These were crystallised from DCM/hexane instead of DCM/MeOH. Examples 12 and 49 20 These remained as oils. Examples 18, 19, 41 and 43 25 These required extended heating and reaction time (up to three days). In some examples function group interconversion reactions provided the depicted compounds. 30 Example 59 WO 03/076407 PCT/AU03/00308 40 To the product of Example 1 (0.1 mmol) and Cs 2

CO

3 (0.2 mmol) in DMF (0.5 ml) was added Mel (5 equivalents) and the mixture was stirred for 30 minutes, during which time the reaction mixture had changed from a deep red-black to a pale orange colour. The reaction mixture was partitioned between EtOAc (5 ml) and 5 water (5 ml), the separated organic layer washed with 1M aq. NaOH (2 x 5 ml) and then water (2 x 5 ml). The organic layer was dried over MgSO 4

.H

2 0, filtered and the solvent evaporated under vacuum to give the product, which was purified using silica gel chromatography (cyclohexane/DCM). Yield 66%. 10 Example 60 This was made and purified exactly as for Example 59 but using benzyl bromide (1 equivalent) instead of methyl iodide as the alkylating agent. Yield 73%. 15 Shown in Table 1 are melting point and biological data for a range of compounds of the invention tested for binding Kv1.3. Those compounds less or not active at Kv1.3 are of interest as being potentially selective for Kv channels other than Kv1 .3. They also may be useful intermediates for the manufacture of compounds having activity at the Kv1.3 channel. 20 WO 03/076407 PCT/AU03/00308 41 TABLE 1 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 1 Me O 324 Kv1.3 Cinnamon Kd peak =750nM needles. Kd end =120nM O Kd area =400nM Selectivity Me over Kv1.5 Kv1.7: is 25-fold. Kd peak =25pM, Kdend =5pM Mp 125 (i.e. phasic) 126 Kv1.1: Kdpeak =12plM Kd end =700nM Kd area =1.2pM IK - no inhibition at 20pM 2 OMe 0 326 Kd peak =800 nM yellow Kd end =300 nM needles OH Mp 112 113 3 0 328 Kd peak =2 pIM Pale yellow needles Mp 113 114 WO 03/076407 PCT/AU03/00308 42 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 4 OMe 0 382 Kd peak = 45 IM Mp 74-75 Block not phasic Granular OH O ~Orange OMe needles 5 oMe O 400 K peak = 30 p.M Mp 122 Block not phasic 124 O'OH OH 6 OMe 0 381 Kd peak = 35 pM Mp 180 o Block not phasic 181 O OH N Me Granular Me H brown solid 7 OMe 0 CI 358.5 Kd peak = 12 piM Mp 160 N IBlock not phasic 161 o X- OH Dark OMe orange needles 8 OMe 0 358.5 Kd peak = 15 pM Mp 121 CI Block not phasic Bright 0OH orange OMe needles 9 OMe 0 358.5 Kd peak = 7 IM Mp 152 ClNBlock not phasic Orange Needles 0 Me WO 03/076407 PCT/AU03/00308 43 EXAM STRUCTURE MW Est. Kd OT HER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 10 OMe 0 349 Kd peak = 20 pM Mp 182 / CN Block not phasic 183 O Orange OMe granules 11 OMe 0 349 Kd peak = 12 ptM Mp 196 Block not phasic 198 O OH CN Red-brown OMe solid 12 OMe 0 439 10 M no effect Dark brown O OH O Not tested against amorphous OMe other channels resin 13 OMe 0 395 Kd peak = 18 LM Mp95 K" t Block not phasic Red < OH orange OMe needles 14 OMe 0 368 Kd peak = 10 [M Mp 105 Kd end = 1.5 pM Dark O OH OEt orange OMe granules 15 OMe 0 F 342 Kd peak 90 LIM Mp133 Kd end = 12 gM Orange solid O OH OMe WO 03/076407 PCT/AU03/00308 44 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 16 OMe 0 342 Kd peak 35 pM Mp 121 / F Kd end 4 ptM 123 eo] -IOH K-Orange OMe solid 17 OMe 0 342 Kd peak 8 pM Mp 129 Kd end = 1 RM Orange O # H F solid OMe 18 OMe 0 340 Kvl.3 OH Kdpeak =5 M O OH Kdend =25OflM OMe Kd area =700nM Kv1.5 Kd peak =16pM Kd end =10pM Kv1.7 Kd 5OpM (time independent) Kv1.1 Kd peak =15RM Kd end =1JIM Kd area =1.7pM IK- NI (5gM) 19 OMe 0 340 Kd peak= 10 gM OH Kd end =0.9 pM OH OH OMe WO 03/076407 PCT/AU03/00308 45 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 20 OMe 0 366 Kd peak = 3 tM Mp 85 block not phasic Dark O OH brown OMe crystals 21 OMe 0 Me 338 Kd peak = 2 LM Mp 121 block not phasic Red orange Oe Powder OMe 22 OMe 0 338 Kd peak = 1.5 ptM Mp 97-98 Me Kd end 300 nM Dark eOH Kbrown OMe crystals 23 OMe 0 338 Kd peak =1.5 LM Mp 148 Kd end = 100 nM Brown O Me needles O OH Me O Me 24 OMe 0 354 Kv1.3- Mp 99 / I OMe Kd Peak = 0.9 t o Dark O O OH 1.1p[LM orange OMe Kd end = 250 to needles 300nM Kd area =800nM (based on peak 1.1 and end 300 result) WO 03/076407 PCT/AU03/00308 46 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) Kv1.5 Kd peak=36LM Kd end =6M IK- NI (20piM) 25 OMe 0 OMe 354 Kd peak 5 pM Mp 117 Kd endj 1 IM 118 Red-brown 0 e OH granular OMe crystals 26 OMe 0 398 Kd peak = 9 IM Mp 139 0 Kdend 1.5 M 140 I> O / OH 0 Dark oMe orange granular crystals 27 OMe 0 NO2 369 Kd peak 15 pM Mp 131 Kd end 5 M 132 0OH Orange Me solid 28 OMe 0 369 5-10% block at 5 Mp 97-98 "_NO 2lM Dark 0 MH brown OMe crystals 29 OMe 0 369 Stocks precipitate Mp 148 Brown

NO

2 needles OMe WO 03/076407 PCT/AU03/00308 47 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 30 OMe 0 F 414 Kd peak 5 iM Mp 112 F Kdend 3.5 M 114 * OH1-:11Orange OMe F solid 31 OMe 0 O CF 3 392 Kd peak = 40 pAM Mp 150 block not phasic 151 0 OH Orange granules OMe 32 OMe 0 392 Kd peak = 40 jiM Mp 123 / 7 CF block not phasic Orange 14 needles OH OMe 33 OMe 0 392 Kd peak = 10 pM Mp 135 CF3Kd end = 4 M Red-brown 7C7 needles O* OH CF 3 OMe 34 OMe 0 416 no effect at 5 pM Mp 111 7 OPh Orange O 1 OH Not tested against needles OMe other channels 35 OMe 0 450.5 no effect at 5 pM Mp 107 108 O( OH Cl Not tested against Orange other channels needles 36 OMe o 484 no effect at 5 M Mp 121 O CF 3 Orange OH Not tested against granular oMe other channels crystals WO 03/076407 PCT/AU03/00308 48 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 37 OMe O 430 no effect at 1 pM Mp 126 0- , H KRed OOH Me Not tested against prisms ome other channels 38 OMe O 374 no effect at 5 pM Mp 131 Orange Not tested against prisms O OH other channels OMe 39 OMe 0 374 no effect at 5 pM Mp 158 Orange O (: OH Not tested against granular OMe other channels crystals 40 OMe 0 349 no effect at 1 M Mp 112 Pale brown O OH Not tested against granular OMe other channels crystals 41 OMe 0 CO 2 H 368 no effect at 20 pM Mp 131 Orange OH Not tested against yellow OMe other channels granules 42 OMe 0 367 Kd peak 14 p.M Mp 61 Kd end =5 pM Red-brown OH NMe 2 prisms OMe 43 OMe 0 OH 340 Kd peak =16 pM Mp 98 Kd end = 8 pM Mustard 7' '7'yellow OMe granular crystals WO 03/076407 PCT/AU03/00308 49 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 44 oMe 0 393 Kd peak = 22 LM Mp 99 Block not phasic Red-brown WOH NMe prisms oMe 45 OMe O 314 Kd peak= 20 tM Mp 127 0 Kd end= 4 pM Orange O ~ OHgranules OMe 46 OMe 0 344 No effect at 20 pM Mp 120 / CH 2 OH 121 O OH Not tested against Orange OMe other channels granules 47 OMe 0 363 No effect at 5 pM Mp 138 \ 140 O OH N Not tested against Orange Q OH H OMe other channels prisms 48 OMe 0 325 Kd peak 20 M Mp 110 Kd end =9 M Orange OH granules O Me 49 OMe 0 325 Kd peak = 20 pM Brown block not phasic amorphous N resin 0 0MO OMe 50 OMe 0 339 Kd peak = 12 piM Mp 86-87 Me block not phasic Pale brown O ~ OH granules OMe WO 03/076407 PCT/AU03/00308 50 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 51 OMe 0 313 Kd peak 30 pM Mp 93 H Kd end 9 M bar n OH brown OMe prisms 52 OMe 0 Me 327 Kd peak =40 gM Mp 87-88 4Kd end D15 pM ark OH brown OMe prisms 53 OMe 0 330 Kd peak = 1.75 pM Cytotoxic S Kd end 3 0 0 nM Mp129 Red OH needles OMe 54 OMe 0 409 Kd peak = 4 pM Cytotoxic S Kd end =250 nM Mp139 O( OH Brown OMe Br needles 55 OMe 0 344 Kd peak = 3 gM Cytotoxic / / Me Kd end = 500 nM Mp1O3 O OH Orange OMe prisms 56 OMe 0 344 Kd peak = 25 pM Mp 131 7 s Kd end= 6 pM Brown Needles OMe PAOPERiJWI Speciacation\BR1 amendeddoc.1506MO Received 15 June 2004 -51 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 57 me 375 No effect at 10 sM Mp 127 S NO2 Dark brown granules N ~ Brown 0O OH granules oMe 59 Me Kd peak =40 RM Amorphous Kd end = 5 gM resin *0OMe Ome 60 61 Me 0 354 OH OH Me OMe 62 OMe 356 OH OH OMe OH 613 Me384 OH OMe Ome- P;\OPER~gc\FullSpeif~iatIos\BRI amededdocISF .Received 15 June 2004 -52 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) 64 otherwise) 64 65. me 392 H OMe 68 67 oe o 444 OH a o OHOH 0 Wes 68 OMe 0 368 Me NOH Me 0 ~ 2 OH OWe 69 AMENDD SHET Received 15 June 2004 P.ADPERXge'.ull SpecUat~auOfl =mdedo-15MMfO -53 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 70 71 72 73 74 OMe 0 356 OH OMe 75 OMe 0 -357 N ~OH S ~OH OMe 76 OMe 0 357 OH OOH OMe WO 03/076407 PCT/AU03/00308 54 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 77 OMe 0 364 SHOH O# I-OH OMe 78 OMe 0 341 OH O#OH OMe 79 0 310 OH OMe 80 OMe 0 350 OH OH OMe 81 OMe 0 340 O u OH OH OMe 82 351 OMe 0 N OH OH OMe 83 OMe O 351 OH N OeOH M e Received 15 June 2004 - P:WERtUgc\Fut 5pcficaiona\BR amendedLdoc-506/04 - 55 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 84 OMe 0 351 OH ~'OH OMe 85 OMe 0 351 A N OH No OMe 86 OMe 0- 352 OH OH -Me 87 88 89 90 P:\PERJgc\FullSpecifications\Bimmcdeddoc-15/06 I Received 15 June 2004 -56 EXAM STRUCTURE MW Est. Kd OTHER' -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 91 92 93 94 95 96 NDED HETl WO 03/076407 PCT/AU03/00308 57 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points "C) otherwise) 97 OMe O 370 OH 0 OP OMe OMe 98 PO3H2 419 OMeo OMe 100 P0 3

H

2 452 OMe0

~CF

2 101 0 32

/CHCO

2 H O H OMe 102 We 0 368 0 OH We 102________ W e_______________________________________0__________ 382_______ ___________________________ _______________ P:AOPERigeiI SpecciflcadOBRI &mded.doc-iSffl&% Received 15 June 2004 -58 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 103 N 392 Me 0 N O OH OMe 104 105 106 OMe 0 420

OSO

3 H O OH OMe 107 OMe 0 368

B(OH)

2 0O - OH OMe 108 OMe O 418 C I1CH 2

PO

3

H

2 ' OH W~e WO 03/076407 PCT/AU03/00308 59 EXAM STRUCTURE MW Est. Kd OTHER -PLE (Kv 1.3 unless (melting NO. specified points *C) otherwise) 109 OMe o 406 N 110 OMe 0 453

CF

2

SO

3 H OMe 111e 382

CH

2

B(OH)

2 o ~OH OMe 112 OMe O 430 /O( 0

CH

2

PO

3

H

2 OMe 113 OMe O

CH

2

SO

3 H o OH OMe 114 OMe O HOH C0 2

H

WO 03/076407 PCT/AU03/00308 60 PROLIFERATION TEST r 3 HI-Thymidine incorporation assay 5 Resting peripheral blood mononuclear cells from healthy volunteers were seeded at 2x10 5 cells per well in medium (RPMI 1640 supplemented 10% fetal calf serum, 2 mM glutamine, 1 mM sodium pyruvate, I % nonessential amino acids, 100 units/mi penicillin, 100 ptg/ml streptomycin and 50 piM fp-mercaptoethanol) in flat bottom 96 well plates (final volume 200 lI). Cells pre-incubated with drug (60 min), 10 were stimulated with 5 ng/ml anti-CD3 Ab) for 48 h. [ 3 H]-Thymidine (1 pCi per well) was added for the last 6 h. Cells were harvested onto glass fibre filters and radioactivity measured in a scintillation counter. All experiments were done in triplicate. Results are reported as normalised for maximum [ 3 H]-thymidine incorporation for controls. 15 Proliferation Restults The proliferation results for Example 1 and 18 are shown in Fig. 1. As will been seen from these results, the compound of Example I suppresses proliferation of 20 human peripheral blood lymphocytes with an EC50 of 1pM, Example 18 with an EC50 of 500 nM, Example 23 with an EC50 of 1.5 pM and Example 24 with an EC50 of I 4M. Flow cytometric measurement of cell viability 25 Jurkat E6-1 and MEL were seeded at 5x10 5 cells/ml in twelve-well plates. Drug (100 nM, I p.M, 2.5 pM and 10 p.M ) was added in a final DMSO concentration of 0.1%. After 48 h of incubation, cells were harvested by sucking them off the plates. Cells were centrifuged, resuspended in 0.5 ml PBS containing I pg/ml 30 propidium iodide (PI), and red fluorescence measured on a FACScan flow cytometer (Becton Dickinson) after 20 min (104 cells of every sample being analyzed). The percentage of dead cells was determined by their PI uptake.

WO 03/076407 PCT/AU03/00308 61 Incubation with 20% DMSO served as a control for setting the gates of the flow cytometer for dead cells. The results are shown in Table 2. Table 2 5 Compounds MEL cells Jurkat T-cells Control 1 3.06 % 2.67 % (0.1% DMSO) Control 2 99.10 % 97.90% (20 % DMSO) Example 1 4.95 % 3.02 % 100 nM Example 1 6.21 % 1.47 % 1 LM Example 1 6.70% 1.78 % 2.5 pM Example 1 5.88% 8.10% 10 pM Example 18 6.89 % 2.57 % 100 nM Example 18 3.60% 2.22 % 1 M Example 18 6.98% 2.59 % 2.5 pM Example 18 4.41% 4.70 % 10 pM Example 24 3.53 % 2.41% 100 nM - 62 Compounds MEL cells Jurkat T-cells Example 24 3.73% 2.81 % 1 pLM Example 24 5.26% 2.31% 2.5 piM Example 24 3.00% 9.8% 10 [tM From the above results it is apparent that the compound of Example 1 has significant therapeutic potential. It blocks the Kv1.3 voltage gated potassium channel in T-lymphocytes, with a Kd (dissociation constant) of 400 nM. Thus, in 5 blocking the Kv1.3 channel in T-lymphocytes, this compound inhibit the immune response, as measured below by the inhibition of T-lymphocyte proliferation in response to stimulation by anti-CD3 antibody (Figure 1). Furthermore, example 1 is non-cytotoxic in-vitro (Table 2) and non-toxic when 30 uM is injected intravenously into mice. 10 Further preferred examples of compounds of the invention include Examples 18 and 24. These compounds have been found to also be non-cytotoxic (see Table 2), non-toxic when injected intravenously into mice, and even more potently antiproliferative (Figure 1). 15 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or 20 group of integers or steps.

- 63 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general 5 knowledge in the field of endeavour to which this specification relates. It would be appreciated by a person skilled in the art the numerous variations and/or modifications may be made to the invention as shown the specific embodiments without departing from the spirit or scope of the invention as broadly 10 described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims (23)

1. A method of intentionally modulating potassium ion channel activity of T cells by the administration of an effective amount of a compound of Formula lb 5 OCH 3 0 R8 CHF CH 1 B CA CI H L H H J A 6 OH OCH 3 lb or pharmaceutically acceptable derivative thereof, wherein 10 R 6 and R 8 are hydrogen or together form a double bond; m = 0 or 1; A is a ring selected from N ' N N 0 OX 0 15 where X is 0, S or NR, where R is hydrogen, lower alkyl or oxygen; - 65 \ and Y X where X is N, and Y is 0, S or NR and R is hydrogen, lower alkyl or oxygen; and where the two dashed lines on the right hand side of the rings indicate the location at which the ring A is fused to the phenyl ring; 5 and ring A is optionally substituted with halo, lower alkyl, benzyl or -C(O)C 6 H 5 ; B is a ring selected from phenyl, naphthalenyl, pyrrolyl, furyl, thiophenyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, pyridinyl, pyryl, pyrimidinyl, indolyl, 10 quinolinyl, isoquinolinyl and a methylenedioxy phenyl ring system (structure C): C and the ring B is optionally substituted with one or more substituents independently selected from 15 a) halo, cyano, -NO 2 , -SO 3 H, -OSO 3 H, -OP0 3 H 2 , -P0 3 H 2 and -B(OH) 2 ; b) -NR'R" (where R' and R" are independently hydrogen or lower alkyl); c) -NR'C(O)R" (where R' and R" are independently hydrogen or lower alkyl); d) phenyl and tetrazolyl; e) -OR, -C(O)R, and -C(O)OR (where R is hydrogen, optionally substituted lower 20 alkyl, optionally substituted phenyl, optionally substituted phenylloweralkyl and the optional substituents are independently selected from lower alkyl, halo and -NR'R" where R' and R" are independently hydrogen or lower alkyl); f) -C(O)NHSO 2 R"' and -S(O) 2 NHC(O)R"' (where R"' is lower alkyl); g) optionally substituted lower alkyl such as -CH 3 , -CH(CH 3 ) 2 , -CH 2 B(OH) 2 , 25 -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CH 2 0PO 3 H 2 , -CH 2 OSO 3 H, -CH 2 C(O)NHSO 2 R"', -CH 2 S(O) 2 NHC(O)R"' (where R"' is lower alkyl), -CH 2 C 6 H 5 , -CH 2 -tetrazolyl, -66 -(CH 2 )nNR'R" (where n is from 1 to 4 and R' and R" are independently hydrogen or lower alkyl), -CF 3 , -CF 2 B(OH) 2 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, -CF 2 0PO 3 H 2 , -CF 2 0SO 3 H, -CF 2 C(O)NHSO 2 R"', -CF 2 S(0) 2 NHC(O)R"' where R"' is lower alkyl, -CF 2 C 6 H 5 and -CF 2 -tetrazolyl; 5 with the proviso when A is unsubstituted furyl, R" is hydrogen, R 6 and R 8 together form a double bond, m is 0, ring B is 4-pyridinyl; and with the proviso ring A is not an unsubstituted cyclopentadiene ring, when R 6 10 and R 8 together form a bond and B is an optionally substituted phenyl or pyridine ring.

2. The method of claim 1 wherein ring B is substituted by -(CH 2 )nR 20 where n is from 0 to 6 and R 20 is selected from hydrogen (where n is other than 0), -OSO 3 H, 15 OP0 3 H 2 , -CO 2 H, tetrazolyl, -B(OH) 2 , -S(0) 2 NHC(O)R', -C(O)NHS(0) 2 R' (where R' is lower alkyl), -OH, -C 6 H 4 0H, -CF 2 PO 3 H 2 and -SO 3 H.

3. The method of claim 1 or 2 wherein ring B is optionally substituted with one or more substituents independently selected from -F, -Cl, -Br, -CN, -NO 2 , -SO 3 H, 20 -SO 3 H, -OP0 3 H 2 , -P0 3 H 2 , -B(OH) 2 , -N(CH 3 ) 2 , -NHC(O)CH 3 , -C 6 H 5 , -tetrazolyl, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 N(CH 2 CH 3 ) 2 , -C 6 H 5 , -OC 6 H

4 CH 3 , -CO 2 H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CH 2 CO 2 H, -CH 2 tetrazolyl, 0 NU -CF 3 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, -CF 2 tetrazolyl and NN 25 4. The method of claim 1 comprising the administration of a compound of the formula Ill or pharmaceutically acceptable derivative thereof -67 OCH3 O R 8 R1 CH LCH---CH B O H OCH3 III where R , R 8 , m and B are as defined in claim 1 and R" is hydrogen, halogen, lower alkyl, benzyl or -C(O)C 6 H 5 .

5 5. The method of claim 1 comprising the administration of a compound of the formula IV or a pharmaceutically acceptable derivative thereof OCH3 O R 11 B Iv OCH3 where R" is hydrogen, halogen, lower alkyl, benzyl or -C(O)C 6 H 5 and B is an optionally substituted ring or ring system selected from phenyl, naphthalenyl 10 pyridinyl, pyrrolyl, furyl, indolyl, quinolinyl, isoquinolinyl, thiophenyl and 0 0

6. The method of claim 1 comprising the administration of a compound of the formula Va or a pharmaceutically acceptable derivative thereof -68 OCH3 O R 15 R"01 R19 OH R R8 OCH3 R1 Va wherein R 11 is hydrogen, halogen, lower alkyl, or -C(O)C 6 H 5 ; 5 R 15 , R 16 , R 17 and R 18 are independently selected from hydrogen, -F, -Cl, -Br, -CN, -NO 2 , -SO 3 H, -OSO 3 H, -OP0 3 H 2 , -P0 3 H 2 , -B(OH) 2 , -N(CH 3 ) 2 , -NHC(O)CH 3 , -C 6 H 5 , -tetrazolyl, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 N(CH 2 CH 3 ) 2 , -OC 6 H 5 , -OC 6 H 4 CH 3 , -CO 2 H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CH 2 CO 2 H, 0 NHI -CH 2 tetrazolyl, -CF 3 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, -CF 2 tetrazolyl and NN 10 R 1 9 is selected from -(CH 2 )nR 20 , where n is from 0 to 6, and R 20 is selected from hydrogen (when n is other than 0), -OSO 3 H, -OP0 3 H 2 , -CO 2 H, tetrazolyl, -B(OH) 2 , -S(O) 2 NHC(O)R', -C(O)NHS(0) 2 R' (where R' is lower alkyl), -OH, -C 6 H 4 0H, -CF 2 PO 3 H 2 and -SO 3 H. 15

7. The method of claim 1 comprising the administration of a compound of the formula Va or a pharmaceutically acceptable derivative thereof -69 OCH3 O R 15 Rii R19 "0 OH R 16'R8 OCH3 R 1 Va wherein R" is hydrogen, halogen, lower alkyl or -C(O)C 6 H 5 ; 5 R 15 , R, 16 R 1 7 and R 18 are independently selected from hydrogen, -F, -Cl, -Br, -CN, -NO 2 , -SO 3 H, -OSO 3 H, -OP0 3 H 2 , -P0 3 H 2 , -B(OH) 2 , -N(CH 3 ) 2 , -NHC(O)CH 3 , -C 6 H 5 , -tetrazolyl, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 N(CH 2 CH 3 ) 2 , -OC 6 H 5 , -OC 6 H 4 CH 3 , -CO 2 H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CH 2 CO 2 H, 0 NH -<k,/ -CH 2 tetrazolyl, -CF 3 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, -CF 2 tetrazolyl and N=N 10 R 1 9 is selected from hydrogen, hydroxy and -OCH 3 .

8. The method of any one of claims 3 to 7 wherein R" is hydrogen. 15

9. The method of claim 1 comprising the administration of a compound of the formula Vb or a pharmaceutically acceptable derivative thereof -70 OCH 3 0 R 8 R1 R19 0 ~ OH R 16 R 18 OCH3 R 1 Vb wherein R 6 and R 8 are hydrogen or together form a double bond; and 5 R 15 , R 16 , R 1 7 , R 1 8 , R 1 9 are independently selected from hydrogen, methyl and methoxy, or R 15 and R 19 , R' 9 and R 1 8 , R" and R 1 7 or R 1 7 and R" together with the phenyl ring to which they are attached forms a methylenedioxy phenyl ring.

10 10. A compound of the formula Ib, OCH 3 0 R 8 C CIC C-=- B CA'0CH L H HiJm A 6 OH OCH 3 lb or a salt or pharmaceutically acceptable derivative thereof, 15 wherein R 6 and R 8 are hydrogen or together form a double bond; m = 0 or 1; - 71 A is a ring selected from N N N **N '' N X where X is N, and Y is 0, S or NR and R is hydrogen, lower alkyl or oxygen; and where the two dashed lines on the right hand side of the rings indicate the location at which the ring A is fused to the phenyl ring; 10 and ring A is optionally substituted with halo, lower alkyl, benzyl or -C(O)CyHg; B is a ring selected from phenyl, naphthalenyl, pyrrolyl, furyl, thiophenyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, pyridinyl, pyryl, pyrimidinyl, indolyl, 15 quinolinyl, isoquinolinyl and a methylenedioxy phenyl ring system (structure C) 100 C and the ring B is optionally substituted with one ore substituents independently selected from - 72 a) halo, cyano, -NO 2 , -SO 3 H, -OSO 3 H, -OP0 3 H 2 , -P0 3 H 2 and -B(OH) 2 ; b) -NR'R" (where R' and R" are independently hydrogen or lower alkyl); c) -NR'C(O)R" (where R' and R" are independently hydrogen or lower alkyl); d) phenyl and tetrazolyl; 5 e) -OR, -C(O)R, and -C(O)OR (where R is hydrogen, optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted phenylloweralkyl and the optional substituents are independently selected from lower alkyl, halo and -NR'R" where R' and R" are independently hydrogen or lower alkyl); f) -C(O)NHSO 2 R'" and -S(O) 2 NHC(O)R'" (where R"' is lower alkyl); 10 g) optionally substituted lower alkyl such as -CH 3 , -CH(CH 3 ) 2 , -CH 2 B(OH) 2 , -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CH 2 0PO 3 H 2 , -CH 2 OSO 3 H, -CH 2 C(O)NHSO 2 R"', -CH 2 S(0) 2 NHC(O)R"' (where R.' is lower alkyl), -CH 2 C 6 H 5 , -CH 2 -tetrazolyl, -(CH 2 )nNR'R" (where n is from 1 to 4 and R' and R" are independently hydrogen or lower alkyl), -CF 3 , -CF 2 B(OH) 2 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, 15 -CF 2 0PO 3 H 2 , -CF 2 0SO 3 H, -CF 2 C(O)NHSO 2 R"', -CF 2 S(O) 2 NHC(O)R"' where R.' is lower alkyl, -CF 2 C 6 H 5 and -CF 2 -tetrazolyl; with the proviso when A is unsubstituted furyl, R 6 and R 8 together form a double bond, m is 0, ring B is not phenyl, 4-dimethylamino phenyl, 4-methyl phenyl, 3- or 20 4-methoxy phenyl, 2,4- or 3,4-dimethoxy phenyl, 2,4,5- or 3,4,5-trimethoxy phenyl, 3-methoxy-4-hydroxy phenyl, 4-(O-benzyl)phenyl, 2-pyridinyl, 3-pyridinyl, 4 pyridinyl, 2-furyl, 3,4-methylenedioxy phenyl, 2-thiophenyl, 4-fluorophenyl, 4 hydroxyphenyl, 4-nitrophenyl, 2-methoxyphenyl or 3-methylphenyl; 25 and with the proviso that ring A is not an unsubstituted cyclopentadiene ring, when R 6 and R 8 together form a bond and B is an optionally substituted phenyl or pyridine ring.

11. The compound of claim 10 wherein ring B is substituted by -(CH 2 )nR 20 30 where n is from 0 to 6 and R 20 is selected from hydrogen (when n is other than 0), - 73 -OSO 3 H, -OPO 3 H 2 , -CO 2 H, tetrazolyl, -B(OH) 2 , -S(0) 2 NHC(O)R', -C(O)NHS(0) 2 R' (where R' is lower alkyl), -OH, -C 6 H 4 0H, -CF 2 PO 3 H 2 and -SO 3 H.

12. The compound of claim 10 or 11 wherein ring B is optionally substituted by 5 F, -Cl, -Br, -CN, -NO 2 , -SO 3 H, -OSO 3 H, -OP0 3 H 2 , -P0 3 H 2 , -B(OH) 2 , -N(CH 3 ) 2 , NHC(O)CH 3 , -C 6 H 5 , -tetrazolyl, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 N(CH 2 CH 3 ) 2 , OC 6 H 5 , -OC 6 H 4 CH 3 , -C0 2 H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 PO 3 H 2 , -CH 2 SO 3 H, CH 2 CO 2 H, -CH 2 tetrazolyl, -CF 3 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, -CF 2 tetrazolyl and 0 NH N--N 10

13. The compound of claim 10, or a salt or pharmaceutically acceptable derivative thereof, of the formula IV OCH3 O R11 B O OH IV OCH3 where R" is hydrogen, lower alkyl, halogen or -C(O)C 6 H 5 and B is an optionally 15 substituted ring or ring system selected from phenyl, naphthalenyl, pyridinyl, pyrrolyl, furyl, indolyl, quinolinyl, isoquinolinyl, thiophenyl and 0

14. The compound of claim 10 wherein ring B is substituted by -(CH 2 )nR 20 20 where n is from 0 to 6 and R 20 is selected from hydrogen (when n is other than 0), -74 -OSO 3 H, -OP0 3 H 2 , -C0 2 H, tetrazolyl, -B(OH) 2 , -S(0) 2 NHC(O)R', -C(O)NHS(O) 2 R' (where R' is lower alkyl), -OH, -C 6 H 4 0H, -CF 2 PO 3 H 2 and -SO 3 H.

15. The compound of claim 13 or 14 wherein B is optionally substituted with one 5 or more substituents independently selected from -F, -Cl, -Br, -CN, -NO 2 , -SO 3 H, -OSO 3 H, -OP0 3 H 2 , -P0 3 H 2 , -B(OH) 2 , -N(CH 3 ) 2 , -NHC(O)CH 3 , -C 6 H 5 , -tetrazolyl, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 N(CH 2 CH 3 ) 2 , -OC 6 H 5 , -OC 6 H 4 CH 3 , -C0 2 H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CH 2 CO 2 H, -CH 2 tetrazolyl, 0 NH -<k,/ -CF 3 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, -CF 2 tetrazolyl and N ~ N 10

16. The compound of claim 10, or a pharmaceutically acceptable derivative thereof, of the formula Va OCH3 O R15 R" R19 O OH R16 RM OCH3 R17 Va where R 1 1 is hydrogen, lower alkyl, halogen or -C(O)C 6 H 5 ; 15 R 15 , R 16 , R 17 and R 18 are independently selected from hydrogen, -F, -CI, -Br, -CN, -NO 2 , -SO 3 H, -OSO 3 H, -OP0 3 H 2 , -P0 3 H 2 , -B(OH) 2 , -N(CH 3 ) 2 , -NHC(O)CH 3 , -C 6 H 5 , -tetrazolyl, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 N(CH 2 CH 3 ) 2 , -OC 6 H 5 , -OC 6 H 4 CH 3 , -75 -CO 2 H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CH 2 CO 2 H, 0 -CH 2 tetrazolyl, -CF 3 , -CF 2 PO 3 H 2 , -CF 2 SO 3 H, -CF 2 tetrazolyl and N N R 1 9 is selected from -(CH 2 )nR 20 , where n is from 0 to 6, and R 20 is selected from 5 hydrogen (when n is other than 0), -OSO 3 H, -OPO 3 H 2 , -CO 2 H, -tetrazolyl, -B(OH) 2 , -S(0) 2 NHC(O)R', -C(O)NHS(0) 2 R', -OR (where R' is lower alkyl), -OR-C 6 H 4 OH, -CF 2 PO 3 H 2 and -SO 3 H.

17. The compound of claim 10, or a pharmaceutically acceptable derivative 10 thereof, of the formula Va OCH 3 O R1 R" R19 0 OH R1 R8 OCH3 R 1 Va where R 11 is hydrogen, lower alkyl, halogen or -C(O)C 6 H 5 ; R 1 5 , R 16 , R 17 and R 18 are independently selected from hydrogen, -OPO 3 H 2 , 15 PO 3 H 2 , -OSO 3 H, -SO 3 H, -CH 2 PO 3 H 2 , -CH 2 SO 3 H, -CO 2 H, -CH 2 CO 2 H, -CF 2 PO 3 , CF 2 SO 3 , -OH, -B(OH) 2 , -OCH 3 , -OCH 2 CH 3 , -CF 3 , -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , C 6 H 5 , -OC 6 H 5 -OC 6 H 4 CH 3 , -tetrazolyl, -CH 2 tetrazolyl, -CF 2 tetrazolyl, -NHC(O)CH 3 , 0 NH -F, -Cl, -Br, -CN, -OCH 2 CH 2 N(CH 2 CH 3 ) 2 , -NO 2 , -N(CH 3 ) and N N and R 1 9 is hydroxy. - 76

18. The compound of any one of claims 13 to 17 wherein R" is hydrogen.

19. The method of claim 1 comprising the administration of a compound of the formula Vlb or a pharmaceutically acceptable derivative thereof OCH 3 0 R8 Ris R19 0 ~ OH R 16 R 18 OCH 3 R17 5 Vb wherein R 6 and R 8 are hydrogen or together form a double bond; and R 15 , R 1 6 , R 17 , R 1 8 , R 19 are independently selected from hydrogen, methyl and 10 methoxy, or R 15 and R 19 , R" and R", R 18 and R 1 7 or R 1 7 and R 16 together with the phenyl ring to which they are attached forms a methylenedioxy phenyl ring.

20. A compound of formula lb according to claim 10 substantially as 15 hereinbefore described with reference to the examples.

21. A process for the production of a compound of formula lb as defined in claim 1, by reacting a compound of the formula Vila with a compound of the formula Villa in the presence of sodium hydroxide, to produce a compound of the 20 formula Ib, and optionally interconverting functional groups:- -77 OCH 3 0 || A C CH3 A OH OCH 3 VIla H -- -[C==I- B NaOH OCH 3 0 C-C--C--B c1 HimCC C L CH H . A H OH Ib OCH 3 where ring A, B and m are as defined in claim 1.

22. The process of claim 21 wherein ring A, B and m are as defined in claim 10. 5

23. A process for the production of a compound of formula lb substantially as hereinbefore described with reference to the examples. 10